Actively Recruiting
Metabolic Tracing of Tumour and T Cells in the Ascites of Ovarian Cancer Patients
Led by British Columbia Cancer Agency · Updated on 2024-08-09
10
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
B
British Columbia Cancer Agency
Lead Sponsor
U
University of Texas Southwestern Medical Center
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are studying the metabolism of cells in the ascites fluid of ovarian cancer patients to better understand the tumour environment. This observational study involves women aged 18 and older who have ascites caused by diagnosed ovarian cancer. The study aims to trace how glucose is taken up and metabolized by tumour and T cells in the ascites. Participants will receive an intravenous infusion of specially labeled glucose ([U-13C]glucose) during their scheduled paracentesis procedure. The infusion starts with 8 grams of labeled glucose in 60 mL over 10 minutes, followed by 4 grams in 30 mL over one hour, continuing until the ascites fluid is drained or up to 5 hours. A continuous glucose monitor tracks blood glucose levels throughout. Samples of ascites fluid collected during the infusion will be kept on ice and analyzed for metabolic activity and metabolite profiles using flow cytometry and mass spectrometry. During the study, participants will wear a glucose monitor before paracentesis and have ascites fluid collected hourly for up to 5 hours. Researchers will measure glucose enrichment and compare metabolic pathways in different cell types within the ascites. They will also correlate metabolic profiles with T cell function. The study involves close monitoring of blood glucose and sample analysis to understand tumour and immune cell metabolism in ovarian cancer ascites.
CONDITIONS
Brief Title
13C-Glucose Tracing of Tumour and T Cells in the Ascites of Ovarian Cancer Patients.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed ovarian cancer of any stage or grade
- Presence of ascites fluid that requires draining
- Any current treatment regimen, including primary or recurrent ascites
- Ability to understand the study and provide informed consent
- Female participants aged 18 years or older
You will not qualify if you...
- Diagnosis of diabetes or abnormal hemoglobin A1C levels
- Blood glucose levels outside the range of 4 - 11.1 mM before infusion
- Receiving chemotherapy treatment during the 5-hour duration of the experiment
- Male gender (study limited to females only)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person) for screening and enrollment
Duration - Up to 5 hours
Participants receive an intravenous infusion of [U-13C]glucose over approximately 5 hours, during which ascites fluid is collected hourly for metabolic analysis.
1 visit (in-person) for glucose infusion and sample collection
Trial Site Locations
Total: 1 location
1
Jennifer Rauw
Victoria, British Columbia, Canada
Actively Recruiting
Research Team
J
Julian J. Lum, PhD
J
Jennifer Rauw, MD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here